Reduced-dose carmustine (300 mg/m2) and melphalan as a conditioning regimen in multiple myeloma patients with CNS involvement: A case series

Reduced-dose carmustine (300 mg/m2) and melphalan as a conditioning regimen in multiple myeloma patients with CNS involvement: A case series

Single-agent melphalan remains the gold standard for conditioning chemotherapy prior to autologous stem cell transplantation (ASCT) in the multiple myeloma (MM) setting. Melphalan's distribution in the central nervous system (CNS) is limited which raises the question if single-agent melphalan i...

Full description

Bibliographic Details
Main Authors: Garrett Rueda, Eric Smith, Nicolas De Padova, Hayley Heers, Ivan Komerdelj
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Current Problems in Cancer: Case Reports
Subjects:
Multiple myeloma
CNS involvement
Carmustine
Autologous stem cell transplant
Conditioning chemotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621923000546

Internet

http://www.sciencedirect.com/science/article/pii/S2666621923000546

Similar Items